Blueprint Medicines Corp. will bank $15 million as an up-front payment from Cheshire, Conn.-based Alexion Pharmaceuticals Inc. as a kick-off to their strategic collaboration that will center on an undisclosed activated kinase target, which is the cause of a rare genetic disease.